Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab - Drug Trials For Money - Paid Clinical Trials

Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab

Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
Conditions:   Advanced Colorectal Carcinoma;   Metastatic Colorectal Carcinoma;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Stage II Colon Cancer;   Stage II Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Esophageal Cancer;   Pancreatic Cancer;   Bile Duct Cancer;   Gastric Cancer;   Gall Bladder Cancer;   Small Bowel Adenocarcinoma
Interventions:   Biological: Bevacizumab;   Drug: Dasatinib;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
Sponsors:   Anne Noonan;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 9, 2021 / by / in
Comments